When should an adult have a blood test for Lyme disease after a tick bite?

When should an adult have a blood test for Lyme disease after a tick bite? - briefly

A blood test is advisable approximately 2–4 weeks after the bite, particularly if the tick remained attached for more than 36 hours or if early symptoms such as rash, fever, or joint pain appear.

When should an adult have a blood test for Lyme disease after a tick bite? - in detail

Serologic testing for Lyme disease in adults should be considered only after the immune response is likely to be detectable. Antibodies typically appear 2–4 weeks after the bite, with IgM emerging first and IgG following after about 4–6 weeks. Testing earlier than this window often yields false‑negative results because the pathogen has not yet stimulated measurable antibody production.

If the characteristic expanding rash (erythema migrans) is present, clinical diagnosis is sufficient and immediate blood work is unnecessary. When the rash is absent, the following schedule is recommended:

  • Day 0–3 post‑bite: No serology; evaluate need for a single dose of doxycycline (≤72 h) for prophylaxis if the tick was attached ≥36 h and the local infection rate is high.
  • Day 7–14: Consider testing only if systemic symptoms (fever, chills, headache, fatigue, arthralgia) are already evident; a negative result does not exclude early infection.
  • Day 21–28: First reliable serology; obtain both IgM and IgG ELISA, followed by confirmatory Western blot if the ELISA is positive.
  • Day 35–42: Repeat testing if the initial study was negative but symptoms persist or worsen; seroconversion is most likely during this period.

In cases where initial testing is negative and the patient remains asymptomatic, no further blood work is required. However, any emergence of new signs—neurological deficits, cardiac involvement, or migratory joint pain—warrants immediate repeat serology, regardless of the elapsed time.

The key principle is to align testing with the expected antibody kinetics while avoiding premature sampling that could mislead clinical management.